Feature

Patient advocacy groups take in millions from drugmakers. Is there a payback?


 


The Arthritis Foundation did not deny receiving the money but said the foundation represents patients, not sponsors. It is “optimistic” about biosimilars’ ability to help patients and save them money, said Anna Hyde, vice president of advocacy and access. “The Foundation supports the Food and Drug Administration’s scientific standards in evaluating the safety and efficacy of biosimilars, and we support policies that encourage innovation and foster a competitive marketplace.”

The Crohn’s & Colitis Foundation maintains “more than an arm’s-length distance” from its donors in the pharmaceutical industry, who have no say over the foundation’s strategic objectives, said president and CEO Michael Osso.

He added that the foundation’s position on biosimilars is “evolving.”

Lupus Foundation CEO Sandra Raymond said she could not explain how her group, also based in Washington, was involved in the coalition. She confirmed the Lupus Foundation received $444,000 from Pfizer in 2015 but said the money was not linked to any relationship with Patients for Biologics Safety & Access.

Pages

Recommended Reading

MDedge Daily News: How European data privacy rules may cost you
MDedge Dermatology
Patients who hide. Patients who seek.
MDedge Dermatology
MDedge Daily News: How gastric bypass helps fight diabetes
MDedge Dermatology
MDedge Daily News: Does more marijuana mean fewer opioids?
MDedge Dermatology
Cutting Edge Technology in Dermatology: Virtual Reality and Artificial Intelligence
MDedge Dermatology
Medicare Part D plans get more flexibility to make midyear changes
MDedge Dermatology
MDedge Daily News: Could gut bacteria trigger lupus?
MDedge Dermatology
Open enrollment 2018: Plan selections down slightly
MDedge Dermatology
MDedge Daily News: Antibiotic resistance leads to ‘nightmare’ bacteria
MDedge Dermatology
Health IT ‘under-users’ outnumber ‘super-users’
MDedge Dermatology